Lamis A Almalki

Dr. Lamis A Almalki

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in Journal of Onco-Nephrology
Verified
Journal Article
Open access
LALamis A Almalki
Lamis A Almalki
NWNina Teresa Weber
Nina Teresa Weber
AKAbhijat Kitchlu
Abhijat Kitchlu
Advances in cancer therapies have allowed for improved cancer outcomes; however, with the benefits of novel treatments, clinicians must recognize associated side effects, including acute kidney injury (AKI). AKI and associated changes in kidney function are particularly consequential in patients with cancer, as these may lead to ineligibility for treatments, delays and dose reductions in therapy as well as exclusion from clinical trials. This in turn has a negative impact on cancer outcomes. In this review, we address anticancer drug-induced AKI, with specific focus on conventional cytotoxic chemotherapies and targeted therapies chemotherapies. We discuss frequently nephrotoxic chemotherapies, including: platinum-based agents (cisplatin, carboplatin, oxaliplatin); methotrexate and its derivative, pemetrexed; gemcitabine; and other systemic therapies frequently complicated by AKI. With respect to targeted therapies, we review both AKI and pseudo-AKI (i.e. serum creatinine elevation related to drug-mediated impairment of tubular creatinine secretion) from multiple classes, including: anaplastic lymphoma kinase (ALK) inhibitors; cyclin-dependent kinase-4/6 (CDK4/6) inhibitors poly-ADP ribose polymerase (PARP) inhibitors; vascular endothelial growth factor (VEGF) and multi-target tyrosine kinase inhibitors, among others. For each therapy, we review mechanisms of injury and associated renal lesions and preventive strategies, where available. Both oncology and nephrology clinicians must be aware of, promptly recognize, and appropriately manage AKI associated with cancer therapies to allow for optimal cancer outcomes.

31 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
LALamis A Almalki
Lamis A Almalki
NWNina Teresa Weber
Nina Teresa Weber
ADAnup Devasia
Anup Devasia
AKAbhijat Kitchlu
Abhijat Kitchlu
Kidney complications are common after hematopoietic stem cell transplantation (HSCT) and contribute substantially to short- and long-term morbidity and mortality. Acute kidney injury (AKI) affects a large proportion of recipients, particularly after allogeneic transplantation, and reflects the combined effects of baseline patient vulnerability, conditioning intensity, calcineurin inhibitor exposure, infection, hemodynamic disturbances, and transplant-specific complications. This review summarizes the epidemiology, risk factors, and major causes of kidney injury after HSCT, with emphasis on a time-based diagnostic approach. Important etiologies include sepsis, marrow infusion syndrome, sinusoidal obstruction syndrome, graft-versus-host disease-associated kidney injury, transplant-associated thrombotic microangiopathy, and glomerular disease. We also discuss emerging therapeutic approaches, including complement-directed therapy for transplant-associated thrombotic microangiopathy and defibrotide for sinusoidal obstruction syndrome. Beyond the acute transplant period, AKI is increasingly recognized as a major determinant of subsequent chronic kidney disease, cardiovascular risk, and impaired long-term survival. Structured surveillance of kidney function, blood pressure, and proteinuria, together with early recognition of transplant-specific syndromes and closer nephrology follow-up in high-risk patients, is therefore essential. Multidisciplinary collaboration between transplant hematology and nephrology is central to improving kidney and overall outcomes across the HSCT continuum.

29 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LALamis A Almalki
Lamis A Almalki
NWNina Teresa Weber
Nina Teresa Weber
ADAnup Devasia
Anup Devasia
AKAbhijat Kitchlu
Abhijat Kitchlu
Kidney complications are common after hematopoietic stem cell transplantation (HSCT) and contribute substantially to short- and long-term morbidity and mortality. Acute kidney injury (AKI) affects a large proportion of recipients, particularly after allogeneic transplantation, and reflects the combined effects of baseline patient vulnerability, conditioning intensity, calcineurin inhibitor exposure, infection, hemodynamic disturbances, and transplant-specific complications. This review summarizes the epidemiology, risk factors, and major causes of kidney injury after HSCT, with emphasis on a time-based diagnostic approach. Important etiologies include sepsis, marrow infusion syndrome, sinusoidal obstruction syndrome, graft-versus-host disease–associated kidney injury, transplant-associated thrombotic microangiopathy, and glomerular disease. We also discuss emerging therapeutic approaches, including complement-directed therapy for transplant-associated thrombotic microangiopathy and defibrotide for sinusoidal obstruction syndrome. Beyond the acute transplant period, AKI is increasingly recognized as a major determinant of subsequent chronic kidney disease, cardiovascular risk, and impaired long-term survival. Structured surveillance of kidney function, blood pressure, and proteinuria, together with early recognition of transplant-specific syndromes and closer nephrology follow-up in high-risk patients, is therefore essential. Multidisciplinary collaboration between transplant hematology and nephrology is central to improving kidney and overall outcomes across the HSCT continuum.